Suven Life Sciences reported positive Phase 1 results for SUVN-I6107, a selective M1-PAM, demonstrating favorable safety, dose-proportional pharmacokinetics, and evidence of CNS activity, supporting advancement into Phase 2 studies.
Written By: Kirti Kumbhar, M. Pharm (QA)
Reviewed By: Pharmacally Editorial Team
Suven Life Sciences has completed the first-in-human Phase 1 clinical trial of SUVN-I6107, a novel muscarinic M1 positive allosteric modulator (M1-PAM) under development for central nervous system (CNS) disorders. The randomized, double-blind, placebo-controlled study met its primary objectives, demonstrating favorable safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), while providing translational biomarker evidence of CNS activity. The results position SUVN-I6107 for Phase 2 development and mark the fifth internally discovered new chemical entity from Suven to reach clinical testing.
Selective M1 Modulation for Cognition
SUVN-I6107 is a potent, highly selective M1-PAM designed to enhance signaling through the muscarinic M1 receptor, a pathway central to cognition, learning, memory, and information processing. Unlike direct agonists, SUVN-I6107 exhibits minimal intrinsic agonist activity and negligible affinity for M2–M5 subtypes, potentially reducing off-target effects. Preclinical studies showed strong brain penetration, high cerebrospinal fluid exposure, robust efficacy in cognition models, and a favorable safety margin, supporting broad application in neurological and neuropsychiatric disorders characterized by cognitive impairment.
Phase 1 Results: Safety and CNS Activity
The Phase 1 program (NCT06705088) enrolled 40 participants in single ascending dose (SAD) cohorts and 24 participants in multiple ascending dose (MAD) cohorts dosed once daily for 14 days. SUVN-I6107 was well tolerated across all evaluated doses, with no dose-limiting toxicities, serious adverse events, or discontinuations.
Treatment-emergent adverse events were mild to moderate and resolved before study completion. PK analyses demonstrated predictable, dose-proportional exposure, with peak plasma concentrations reached within two to six hours and a half-life of seven to eleven hours.
No clinically meaningful sex-related differences or food effects were observed, supporting flexible administration. Translational biomarker assessments confirmed CNS engagement, with signals of increased alertness and enhanced information processing.
Management Commentary
Chairman and Managing Director Venkat Jasti described the study completion as a milestone for Suven’s M1-PAM program and a testament to the company’s neuroscience research productivity.
Chief Scientific Officer Ramakrishna Nirogi emphasized that integrating translational biomarkers with PK, PD, and safety assessments provided early evidence of CNS activity that will inform Phase 2 strategies.
Path Forward
With Phase 1 successfully completed, Suven plans to advance SUVN-I6107 into Phase 2 clinical studies targeting CNS disorders where cognitive dysfunction remains a major unmet need. Detailed findings are expected to be presented at upcoming scientific conferences and published in peer-reviewed journals, further establishing SUVN-I6107 as a differentiated candidate in the company’s expanding neuroscience pipeline.
Reference
About the Writer
Kirti Kumbhar (LinkedIn) is an M.Pharm graduate with experience in Quality Assurance at Lupin Limited and a strong interest in clinical research, regulatory affairs, and Trial Master File (TMF) management. She has developed knowledge of regulatory documentation, quality systems, compliance, and healthcare research through her professional experience. Passionate about clinical development and continuous learning, Kirti is committed to supporting high-quality healthcare documentation, regulatory excellence, and research-driven healthcare advancements.